by Madaline Spencer | Jul 31, 2025
The U.S. Food and Drug Administration (FDA) has approved Doptelet (avatrombopag) for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients one year and older who have had insufficient response to prior therapy. ITP is a rare bleeding...
by Madaline Spencer | Jul 30, 2025
Paula Rodríguez-Ortero, MD, PhD, Hematologist at the University of Navarra, discusses results of PD-1 inhibitor combination therapy in patients with multiple myeloma (MM). MM is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal...
by Madaline Spencer | Jul 28, 2025
Laura Adang, MD, PhD, Assistant Professor at Perelman School of Medicine at University of Pennsylvania, discusses a cohort study conducted analyzing pre-diagnostic symptoms and time-to-diagnosis in patients with metachromatic leukodystrophy (MLD). MLD is...
by Madaline Spencer | Jul 25, 2025
John Stone, MD, Professor of Medicine at Harvard Medical School and Edward A. Fox Chair in Medicine at Massachusetts General Hospital, discusses data on rilzabrutinib in the treatment of IgG4-related disease (IgG4-RD). IgG4-RD is an immune-mediated...
by Madaline Spencer | Jul 24, 2025
Jack Johnson, Co-Founder and Executive Director of FSIG, discusses symptom and treatment burden in Fabry disease. Fabry disease is a rare lysosomal storage disease characterized by a deficiency in the enzyme alpha-galactosidase (alpha-GAL). Alpha-GAL...
